Catherine Humbrecht

Établissement Français Du Sang Grand Est
Strasbourg, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Epidemiologic Study of Transfusion-Related Alpha-Gal Syndrome.

Epidemiologic Study of Transfusion-Related Alpha-Gal Syndrome.

Journal: JAMA internal medicine
Published: August 24, 2026

Pathogen-reduced platelet concentrates in France: Impact on the risk of transfusion-transmitted infections, 2017-2024.

Pathogen-reduced platelet concentrates in France: Impact on the risk of transfusion-transmitted infections, 2017-2024.

Journal: Vox sanguinis
Published: September 17, 2025

Association between group B major ABO-incompatible platelet or plasma transfusion and severe allergic reactions: A nationwide haemovigilance analysis suggesting a role for α-gal syndrome. A Biomedical Excellence for Safer Transfusion Collaborative study.

Association between group B major ABO-incompatible platelet or plasma transfusion and severe allergic reactions: A nationwide haemovigilance analysis suggesting a role for α-gal syndrome. A Biomedical Excellence for Safer Transfusion Collaborative study.

Journal: Vox sanguinis
Published: August 07, 2025

ABO-mismatched platelet and plasma transfusion practices and the potential for transfusion-related alpha-gal syndrome: The Biomedical Excellence for Safer Transfusion Collaborative Study.

ABO-mismatched platelet and plasma transfusion practices and the potential for transfusion-related alpha-gal syndrome: The Biomedical Excellence for Safer Transfusion Collaborative Study.

Journal: Transfusion
Published: May 19, 2025

Implementation of a whole blood programme within a blood service: Practical guidance for blood providers.

Implementation of a whole blood programme within a blood service: Practical guidance for blood providers.

Journal: Vox sanguinis
Published: April 24, 2025

Anti-HLA class I IgG subclasses skew platelet activation mechanisms in transfusion refractoriness.

Anti-HLA class I IgG subclasses skew platelet activation mechanisms in transfusion refractoriness.

Journal: Haematologica
Published: March 05, 2025

Platelet component safety in the era of new advancements in bacterial screening and pathogen reduction: A congress report of the 2024 ISBT Transfusion-Transmitted Infectious Diseases Working Party, Bacteria Subgroup.

Platelet component safety in the era of new advancements in bacterial screening and pathogen reduction: A congress report of the 2024 ISBT Transfusion-Transmitted Infectious Diseases Working Party, Bacteria Subgroup.

Journal: Vox sanguinis
Published: February 03, 2025

Clinical impact of Amotosalen and UV-A treatment (INTERCEPT™ Blood System) for platelet concentrate preparation in cardiac surgery.

Clinical impact of Amotosalen and UV-A treatment (INTERCEPT™ Blood System) for platelet concentrate preparation in cardiac surgery.

Journal: Blood transfusion = Trasfusione del sangue
Published: December 16, 2024

Current transfusion practice and need for new blood products to ensure blood supply for patients with major hemorrhage in Europe.

Current transfusion practice and need for new blood products to ensure blood supply for patients with major hemorrhage in Europe.

Journal: Transfusion
Published: December 30, 2022

Efficacy of Serotherapy on an N501Y Variant of SARS-CoV-2 in a Patient With Chronic Lymphocytic Leukemia.

Efficacy of Serotherapy on an N501Y Variant of SARS-CoV-2 in a Patient With Chronic Lymphocytic Leukemia.

Journal: HemaSphere
Published: June 09, 2021

Impact of COVID-19 and lockdown regarding blood transfusion.

Impact of COVID-19 and lockdown regarding blood transfusion.

Journal: Transfusion
Published: January 11, 2021

Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial.

Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial.

Journal: European journal of haematology
Published: December 18, 2020
Showing 1-12 of 22

Last Updated: 09/26/2026